It is increasingly common practice for researchers to scan DNA sequence data from tumor biopsies of cancer patients—the idea being that the presence of mutations might inform tailored treatments or prognoses. It is not common, however, to sequence these patients’ normal DNA, which, according the authors of a new study, is a serious omission. George Demetri, professor of medicine at Dana-Farber Cancer Institute, and Daniel Haber, Kurt J. Isselbacher/Peter D. Schwartz Professor of Oncology at Massachusetts General Hospital, are mentioned.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure